GNI Group operates pharmaceutical, biotechnology, medical-technology and investment businesses. Its pharmaceutical operations span research, development, manufacturing and sales, with Gyre Pharmaceuticals marketing Etuary, a pirfenidone medicine for idiopathic pulmonary fibrosis, in China since 2014.
Drug-development programs include F351 for liver fibrosis caused by hepatitis B and research using Cullgen's targeted-protein-degradation platform, focused on cancer, inflammation and pain. The medical-technology business operates biomaterials companies, while the group headquarters coordinates investment, partnerships and business development. The group had 990 consolidated employees as of December 2025.
0
open positions at GNI Group
No live listings from GNI Group right now — browse all Tokyo software jobs instead.